新华制药：获得缬沙坦胶囊药品注册证书

Core Viewpoint - The approval of Valsartan capsules by the National Medical Products Administration is a significant milestone for the company, enhancing its cardiovascular product line and competitive position in the market [1] Group 1: Product Approval - The company has received the drug registration certificate for Valsartan capsules (80mg), classified as a prescription drug and a Class 4 chemical drug [1] - The drug is indicated for the treatment of mild to moderate primary hypertension and is included in the Class A medical insurance category [1] Group 2: Market Potential - The sales revenue for Valsartan capsules in Chinese public medical institutions is estimated to be approximately 1.82 billion yuan in 2024 [1] - The company submitted the application for market approval in September 2024, which was accepted, and the approval is expected by December 2025 [1] Group 3: Competitive Advantage - The approval of Valsartan capsules will enrich the company's product line for cardiovascular diseases, thereby enhancing its competitiveness in the pharmaceutical market [1] - However, the sales of the drug may be influenced by various factors such as policies and market conditions, indicating potential uncertainties [1]